Form 4: BioLife Solutions Director Acquires Restricted Stock
Insider Transaction Report
BioLife Solutions director Timothy L. Moore acquired 8,170 shares of common stock as restricted stock under the company's 2023 Performance Incentive Plan.
Summary
- Timothy L. Moore, a Director of BioLife Solutions Inc. (BLFS), acquired 8,170 shares of common stock.
- The transaction occurred on February 24, 2026.
- These shares were granted as restricted stock pursuant to the BioLife Solutions 2023 Performance Incentive Plan.
- The restricted stock will fully vest on January 2, 2027, which is the first anniversary of the initial vesting date of January 2, 2026.
- Following this transaction, Timothy L. Moore beneficially owns a total of 44,943 shares of common stock.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's acquisition of shares, even through a grant, generally indicates continued alignment with the company's long-term success and confidence in its future.
Positives
- A director acquiring additional shares, even through a grant, can signal confidence in the company's future prospects and long-term strategy.
- The grant is part of a performance incentive plan, which aligns management's interests with shareholder value creation by tying compensation to future company performance.
Risks
- This Form 4 filing does not contain information regarding company-specific risks or broader market risks.
Future Outlook
This filing does not provide forward-looking statements or guidance regarding the company's future performance, focusing solely on an insider stock transaction.
Industry Context
StockSavvy.ai notes that restricted stock grants are a common form of executive and director compensation across various industries, designed to incentivize long-term performance and align interests with shareholders. This grant to a director at BioLife Solutions is consistent with standard corporate governance practices for rewarding and retaining key personnel.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Plan Utilization | The restricted stock grant was made pursuant to the BioLife Solutions 2023 Performance Incentive Plan, indicating the ongoing use of established compensation frameworks for directors. | 2026-02-24 | Reinforces alignment of director incentives with long-term company performance and shareholder interests. |
Stakeholder Impact
- Shareholders: The grant increases a director's beneficial ownership, potentially signaling confidence in the company's future and aligning interests with long-term shareholder value.
- Management/Directors: Timothy L. Moore's compensation package is enhanced with a long-term incentive tied to company performance, aiding in retention and motivation.
Next Steps
- The restricted stock granted to Timothy L. Moore is scheduled to fully vest on January 2, 2027.
Key Dates
| Date | Description |
|---|---|
| 2026-01-02 | Initial vesting date reference for the restricted stock grant. |
| 2026-02-24 | Date of acquisition (grant) of 8,170 shares of common stock by Timothy L. Moore. |
| 2026-02-26 | Date the Form 4 was signed and filed with the SEC. |
| 2027-01-02 | Date when the restricted stock granted to Timothy L. Moore will fully vest. |
Keywords
BioLife Solutions, BLFS, Timothy L. Moore, Insider Trading, Form 4, Restricted Stock, Stock Grant, Director Compensation, Performance Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.